Loading
Viemed Healthcare, Inc. Stock: price and insider trades · United States
No insider purchase over the last 90 days. The latest was filed 14 May 2024.
Viemed Healthcare, Inc.: what insiders have been doing
Viemed Healthcare, Inc., classified in the Healthcare & Pharma sector, is a listed company. Its insiders report their share dealings to SEC (Form 4). Over the twelve months to 18 October 2026, the company's managers filed 76 filings, from 22 insiders.
Only sales appear on the open market, 8 sales in all totalling €472k, filed by 4 insiders. The totals exclude 1 filing filed without an amount. Biggest ticket of the year: €258k, sold by Moore Michael and made public on 20 March 2026.
Filings reach the SEC (Form 4) feed a median of 2 days after the trade. For comparison, the SEC allows two business days to file a Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning.
For context, the typical company on the same exchange (median of 5,812 companies) published 19 filings over the same period, against 76 filings here. Over the whole record (from 2021), the tally stands at 1 purchase and 11 sales. On the fundamentals side, the SEC filing (10-K) for the period ending 31 December 2025 lists revenue at 270.3 m USD and net income at 14.9 m USD.
For comparison within the same sector, see the insider buying recorded at Cooper Companies, Inc. and Cytosorbents Corp. These figures are compiled from regulatory filings published by SEC (Form 4). They describe what insiders did and are not a recommendation.
Insider Decl.
199
Thresholds
n/a
Buy Volume
€2,171
1 ops. · all time
Sell Volume
€826,473
11 ops. · all time
Who traded when
BuySaleTimothy Lee Smokoff5 sales
Moore Michael2 sales
Cambre Jerome1 sale
Frazier William1 sale
Smokoff Timothy1 sale
William Dana Frazier1 sale
Since the insiders bought
- -2.6%Entry US$6.92 · Close at T+365 US$6.74
Entry is the close on the day after publication, the first price a reader could act on. Prices in the listing currency. Past moves are not a forecast.
Analyst consensus: bullish or bearish?
Analysts rate Viemed Healthcare, Inc. Buy (bullish), based on 2 analysts. Average price target: US$12.50.
Fundamental score
Ranked 4,852 of 24,148 companies
66.8
score / 100
Value64
Quality70
FCF yld3.3%
Earn yld4.1%
EV/EBITDA7.3x
ROE10%
Gross mgn58%
Net mgn5.5%
Debt/EBITDA0.3x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Financial data
as of FY 2025FY ended December 2025 · cache
US$9.61
Analyst consensus
2 analystsBuy
US$11.00Target US$12.50(+30%)US$14.00
Income statement
RevenueUS$270.3M
Gross profitUS$155.5M58% margin
EBITDAUS$51.6M19% margin
Net incomeUS$14.9M4.8% margin
Valuation
PER (trailing)26.7x
P/Book2.5x
Beta1.04
Balance sheet & cash
Market capUS$366M
Total debtUS$15.9M
Free Cash FlowUS$11.9M
Debt / Equity8%
Profitability & ownership
ROE10.5%
ROA8.2%
% insiders13.9%
% institutions70.7%
Last declaration on 20 August 2026
Declarations199 total
323,758 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766884
323,758 sharesRights Restricted Share UnitsTSXSEDI:4766883
90,429 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766877
Rights - Restricted Stock Units (Shares Only)TSXSEDI:4766874
90,429 sharesRights Restricted Share UnitsTSXSEDI:4766872
157,092 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766868
157,092 sharesRights Restricted Share UnitsTSXSEDI:4766867
226,459 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766865
226,459 sharesRights Restricted Share UnitsTSXSEDI:4766863
20,824 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766861
20,824 sharesRights Restricted Share UnitsTSXSEDI:4766860
76,666 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766858
76,666 sharesRights Restricted Share UnitsTSXSEDI:4766855
36,491 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766852
36,491 sharesRights Restricted Share UnitsTSXSEDI:4766849
15,029 sharesCommon SharesTSXSEDI:4766845
15,029 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766843
12,174 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766840
703 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766836
703 sharesRights Restricted Share UnitsTSXSEDI:4766835
15,029 sharesCommon SharesTSXSEDI:4766834
15,029 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766826
12,174 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766825
703 sharesRights - Restricted Stock Units (Shares Only)TSXSEDI:4766823
703 sharesRights Restricted Share UnitsTSXSEDI:4766822
25 of 199 declarations
About Viemed Healthcare, Inc.
Viemed Healthcare, Inc. (ticker VMD) is a U.S.-focused healthcare company listed on the Nasdaq Stock Market in the United States, and it is best understood as a specialized provider of home-based respiratory care and post-acute medical services. The company was founded in 2006 as Sleep Management by Casey Hoyt and Michael Moore and was rebranded as VieMed in 2014. Its principal operating headquarters is in Lafayette, Louisiana, while the legal entity is incorporated in British Columbia, reflecting a cross-border corporate structure that is somewhat unusual for a U.S.-listed healthcare provider. ([viemed.com](https://www.viemed.com/about-us/?utm_source=openai))
Viemed’s core business centers on home medical equipment (HME) and post-acute respiratory healthcare services, with a strong emphasis on chronic respiratory conditions. Its service offering includes home ventilation, sleep apnea-related PAP therapy and resupply, and broader clinical support designed to help patients transition from facility-based care into the home setting. The company’s model is built around high-touch, technology-enabled care delivery, supported by licensed respiratory therapists and other clinical staff who provide patient education, therapy adherence support, and ongoing monitoring. In addition to respiratory care, Viemed has expanded into healthcare staffing and recruitment, offering workforce solutions to external healthcare organizations that face clinician shortages. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729149/000172914926000009/vmd-20251231.htm?utm_source=openai))
Read moreShow less
From a competitive perspective, Viemed occupies a focused niche within the broader home healthcare and durable medical equipment market. Its value proposition is rooted in the shift toward lower-cost care settings, especially for chronic respiratory disease management, where home treatment can improve convenience and potentially reduce hospital readmissions. The company states that it serves patients in all 50 U.S. states, which gives it national reach even though its operating model is concentrated in a specialized care segment rather than a broad hospital-supply platform. That specialization can be a source of differentiation against larger diversified healthcare suppliers, particularly where clinical expertise and payer relationships matter. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729149/000172914926000009/vmd-20251231.htm?utm_source=openai))
Recent developments have been constructive. On May 5, 2026, Viemed reported first-quarter 2026 results and updated its full-year outlook, highlighting continued growth across key patient metrics. Earlier, on March 4, 2026, the board approved a share repurchase program authorizing purchases of up to 1,930,131 common shares, or roughly 5% of the shares outstanding at that time. The company continues to report quarterly and annual results through SEC filings and investor materials, and its Nasdaq listing under symbol VMD provides direct exposure to U.S. public-market investors. ([sec.gov](https://www.sec.gov/Archives/edgar/data/1729149/000172914926000028/q12026earningsrelease.htm?utm_source=openai))
Recent ranked signals in the same sector
Purchases our model currently ranks for the recommendations list.
All recommendations
